|[April 16, 2014]
RBCC Bioprinting Partner Expands Brand Awareness Campaign
MIRAMAR BEACH, Fla. --(Business Wire)--
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D
Biosciences (n3D), has presented their groundbreaking technology at two
high-profile events in recent weeks as part of a campaign to build brand
awareness around the revolutionary BiO Assay system.
At the 53rd Annual Meeting and ToxExpo of the Society of
Toxicology in Phoenix, n3D delivered a poster session presentation
titled, "A Novel High-Concept Assay for Drug Toxicity Screening." The
largest event of its kind, the Society's annual meeting brought together
more than 6,000 toxicologists from more than 50 countries.
Earlier this month, n3D shared a booth at the 105th Annual Meeting of
the American Association for Cancer Research in San Diego. A premiere
cancer research event, the meeting was host to about 18,000 researchers,
patient advocates and other professionals in the cancer field from
around the world.
By presenting and exhibiting at such landmark events, n3D is helping to
spread the word amongst international researchers about its incredible
breakthrough technology, the BiO Assay. The BiO Assay is the world's
first commercially available 3D bioprinting system designed for high
throughput and high-content drug screening. The automated toxicity assay
uses biocompatible magnetic nanoparticles to print cells into 3D
structures much faster and more affordably than competing bioprinting
tech currently on the market.
"These events are how the latest knowledge in the fields of toxicology
and cancer research is spread," said RBCC CEO Kimberly Palmer. "They are
important showcases for new technologies such as the BiO Assay, and
they're only the beginning of the international brand awareness campaign
that our joint venture has planned for 2014."
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To TMCnet.com's Homepage ]